Seattle Genetics & Astellas bag accelerated approval for PADCEV™
Category: #health  By Mateen Dalal  Date: 2019-12-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Seattle Genetics & Astellas bag accelerated approval for PADCEV™

Seattle Genetics, Inc., a biotechnology company based in U.S., and Astellas Pharma Inc. have recently revealed that the U.S. Food and Drug Administration (FDA) has given PADCEV™ an accelerated approval for treating adult patients with metastatic or locally advanced urothelial cancer. It would be given to patients that have gone through platinum-containing chemotherapy and a PD-1/L1 inhibitor in the past.

According to reliable sources, the remarkable tumor response rate of PADCEV has led to its approval under the FDA’s Accelerated Approval Program. Continued approval would still be subject to the drug’s description and verification of clinical benefit in confirmatory studies.

Apparnetly, PADCEV would be the first-ever treatment to be approved by the FDA in the U.S for advanced urothelial cancer patients . It is a novel ADC (antibody-drug conjugate) that is formulated against Nectin-4, a protein found on top of cells and is highly expressed in bladder cancer.

According to Roger Dansey, M.D., Chief Medical Officer, Seattle Genetics, PADCEV marks as the first approved ADC for patients suffering from urothelial cancer. This approval is a result of the innovative work that both the company has done on this technology.

Prior to this news, Seattle Genetics had made headlines when it bagged approval for ADCETRIS® in the supplemental New Drug Submission from Health Canada. As per the approval, ADCETRIS would be used in combination with CHP chemotherapy for the treatment of untreated PTCL (peripheral T-cell lymphoma)-NOS (not otherwise specified), angioimmunoblastic T-cell lymphoma (AITL) or sALCL (systemic anaplastic large cell lymphoma) in adult patients whose tumors express CD30.

Commenting on which, Dansey said that with this new indication for ADCETRIS, eligible patients and physicians in Canada can have access to this drug for treating frontline CD30-expressing PTCL, a key milestone supporting the firms vision to continue expanding ADCETRIS globally.

Source Credit: https://investor.seattlegenetics.com/press-releases/news-details/2019/FDA-Grants-Accelerated-Approval-to-Astellas-and-Seattle-Genetics-PADCEV-enfortumab-vedotin-ejfv-for-People-with-Locally-Advanced-or-Metastatic-Urothelial-Cancer-the-Most-Common-Type-of-Bladder-Cancer/default.aspx

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Microsoft to fix an active security flaw in Internet Explorer
Microsoft to fix an active security flaw in Internet Explorer
By Mateen Dalal

Microsoft, the renowned American tech giant, reportedly verified the presence of a security flaw that is affecting Internet Explorer (IE) and is being used by hackers. The company also said it is working to find a fix for this bug, which would be rel...

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...